| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V1009 | ZM 336372 | 208260-29-1 | ZM 336372 (ZM-336372; ZM336372) is a novel, potent and selective c-Raf kinase inhibitor with potential anticancer activity. |
|
V2761 | AD80 | 1384071-99-1 | AD80 is a novel multikinase inhibitor that shows strong activity against human RET, BRAF, S6K, and SRC but were much less active than either AD57 or AD58 against mTOR. |
|
V1013 | Agerafenib (CEP-32496; RXDX-105; AC013773) | 1188910-76-0 | Agerafenib (formerly RXDX105; AC013773;RXDX-105;CEP-32496;AC-01377)is a potent and orally bioactive inhibitor of BRAFV600E and c-Raf with potential antitumor activity. |
|
V1006 | AZ 628 (AZ-628; AZ628) | 878739-06-1 | AZ-628 (AZ628; AZ 628) is a novel, selective, and orally bioavailable Raf inhibitor with potential antineoplastic activity. |
|
V4710 | BI-882370 | 1392429-79-6 | BI-882370 (BI 882370), structurally similar to vermurafenib, is a novel, highly potent and selective BRAF inhibitor with anticancer activity. |
|
V99901 | Brimarafenibum | 1643326-82-2 | Brimarafenib is a rapidly accelerating fibrosarcoma (Raf) kinase inhibitor with antitumor effects. |
|
V2661 | CCT196969 | 1163719-56-9 | CCT196969 (CCT-196969) is a novel, orally bioavailable, pan-RAF inhibitor (IC50 = 0.1 μM) with anti-SRC and anticancer activity. |
|
V134934 | EGFR/BRAFV600E-IN-4 | EGFR/BRAFV600E-IN-4 is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. | |
|
V1005 | GDC-0879 | 905281-76-7 | GDC-0879 (AR-00341677;GDC-0879; AR00341677) is a novel, potent, highly selective, and orally bioavailable B-Raf kinase inhibitor with potential antitumor activity. |
|
V1011 | GW5074 | 220904-83-6 | GW5074 (GW-5074; GW 5074) is a novel, potent and selective c-Raf inhibitor with potential neuroprotective activity. |
|
V80402 | ISIS 5132 sodium (CGP 69846A sodium; ISIS 9271 sodium) | ISIS 5132sodium is an oligonucleotide that specifically downregulates c-raf expression. | |
|
V138097 | ISIS 5132 sodium scrambled negative control | The ISIS 5132 sodium scrambled negative control is a negative control with the sequence of ISIS 5132 sodium salt scrambled. | |
|
V97885 | LSN3074753 | 1455031-68-1 | LSN3074753 is a LY3009120-class drug that is a pan-RAF and Raf dimer inhibitor. |
|
V4222 | LUT-014 | 2274819-46-2 | LUT014 is a novel, potent and topical B-Raf Inhibitor which is a proprietary, first-in-class, small molecule allowing administration of EGFR (Epidermal Growth Factor Receptor) Inhibitors to patients without interruptions caused by typical cutaneous side effects. |
|
V1015 | LY3009120 (DP-4978) | 1454682-72-4 | LY03009120 (DP4978;LY-3009120;LY-03009120;DP-4978) is a novel and potent pan-Raf inhibitor with potential anticancer activity. |
|
V1007 | NVP-BHG712 (BHG712) | 940310-85-0 | NVP-BHG712 (NVP BHG-712;NVP BHG712;BHG-712) is a selective and orally bioavailable EphB4 inhibitor with potential anticancer activity. |
|
V1002 | PLX-4720 | 918505-84-7 | PLX4720 (PLX-4720; PLX 4720), a 7-azaindole/pyrrolopyridine-based vemurafenib derivative discovered by a structure-guided discovery approach, is a novel, potent and selective inhibitor of B-RafV600E mutant with potential antitumor activity. |
|
V2666 | PLX7904 | 1393465-84-3 | PLX7904 (also known as PLX-7904; PB04; PB-04) is a novel potent and selective paradox-breaker B-Raf inhibitor with anticancer activity. |
|
V117622 | RAF1 YDYD Recombinant Human Active Protein Kinase | Ras-related factor 1 (RAF1) belongs to the RAF protein kinase family, also known as C-Raf. | |
|
V2920 | RAF709 | 1628838-42-5 | RAF709 is a novel and potent inhibitor of the Raf kinase B/C isoforms (compound example 131 from patent WO2014151616A1) developed through a hypothesis-driven approach focusing on drug-like properties. |